Publication Name	World Journal of Gastroenterology
Manuscript ID	79690
Country	Japan

Received	2022-09-02 08:27
Peer-Review Started	2022-09-02 08:33
To Make the First Decision
Return for Revision	2022-10-20 18:37
Revised	2022-11-07 12:42
Second Decision	2022-12-07 03:23
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2022-12-07 17:16
Articles in Press	2022-12-07 17:16
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-12-20 23:59
Publish the Manuscript Online	2022-12-27 10:06

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	COVID-19 vaccination and liver disease
Manuscript Source	Invited Manuscript
All Author List	Sotaro Ozaka, Takashi Kobayashi, Kazuhiro Mizukami and Kazunari Murakami
Funding Agency and Grant Number
Corresponding Author	Sotaro Ozaka, MD, PhD, Assistant Professor, Department of Gastroenterology, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama, Yufu 879-5593, Oita, Japan. ozakaso@oita-u.ac.jp
Key Words	COVID-19 vaccine; Liver disease; Side effect; Liver injury; Immune-related hepatitis; Autoimmune hepatitis
Core Tip	Patients with chronic liver disease (CLD), including cirrhosis, are a high-risk group for severe coronavirus disease 2019 (COVID-19). Presently, the results of several clinical trials for measuring the efficacy and safety of the available COVID-19 vaccines in patients with CLD have been reported. Given the increased rates of severity and mortality of COVID-19 in patients with CLD, the importance of aggressive vaccination in the effective management of severe acute respiratory syndrome coronavirus 2 infection should be emphasized. Although liver injury following COVID-19 vaccination has also been reported, it is infrequent and is not a factor in vaccine hesitancy.
Publish Date	2022-12-27 10:06
Citation	Ozaka S, Kobayashi T, Mizukami K, Murakami K. COVID-19 vaccination and liver disease. World J Gastroenterol 2022; 28(48): 6791-6810
URL	https://www.wjgnet.com/1007-9327/full/v28/i48/6791.htm
DOI	https://dx.doi.org/10.3748/wjg.v28.i48.6791

Full Article (PDF)	WJG-28-6791.pdf
Full Article (Word)	WJG-28-6791.docx
Manuscript File	79690_Auto_Edited-LM.docx
Answering Reviewers	79690-Answering reviewers.pdf
Audio Core Tip	79690-Audio core tip.mp4
Conflict-of-Interest Disclosure Form	79690-Conflict-of-interest statement.pdf
Copyright License Agreement	79690-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	79690-Language certificate.pdf
Peer-review Report	79690-Peer-review(s).pdf
Scientific Misconduct Check	79690-Bing-Fan JR-2.png
Scientific Editor Work List	79690-Scientific editor work list.pdf
CrossCheck Report	79690-CrossCheck report.pdf
CrossCheck Report	79690-CrossCheck.png